The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and review staff entitled ``Best Practices for Communication Between IND Sponsors and FDA During Drug Development.'' The purpose of this guidance is to describe best practices and procedures for timely, transparent, and effective communications between investigational new drug application (IND) sponsors and FDA at critical junctures in drug development, which may facilitate earlier availability of safe and effective drugs to the American public.
Document
Best Practices for Communication Between Investigational New Drug Sponsors and Food and Drug Administration During Drug Development; Draft Guidance for Industry and Review Staff; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and review staff entitled ``Best Practices for Communication Bet...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
80 FR 76504
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Best Practices for Communication Between Investigational New Drug Sponsors and Food and Drug Administration During Drug Development; Draft Guidance for Industry and Review Staff; Availability,” thefederalregister.org (December 9, 2015), https://thefederalregister.org/documents/2015-30931/best-practices-for-communication-between-investigational-new-drug-sponsors-and-food-and-drug-administration-during-drug-.